JOURNAL OF HEPATOLOGY-期刊论坛，投稿经验-MedSci.cn

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2024-12-16 1475d94am10暂无昵称来自安徽省

with editor接近1个月 Decision in Process接近一周效率真的很低

31 5

展开5条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2024-11-25 1475d94am10暂无昵称来自安徽省

with editor 12天了，好焦虑

399 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2023-05-21 1ddf3775m09(暂无匿称) 来自上海

请问投稿后一般with editor几天会送审？

295 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2023-07-20 121d577cm33(暂无昵称) 来自上海

审稿速度:2.0 | 投稿命中率:25.0
偏重的研究方向：肝癌
经验分享：with editor 1周，10号送外审，期待中

207 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2022-12-30 ms5000001189510088 来自四川省

想问问这个杂志收中药单体的机制研究文章吗？

262 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2022-08-25 121ec805m86(暂无昵称)

With Editor 一个周了，不知道会怎么样

270 2

展开2条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2015-10-09 lss7259

审稿速度:1.0 | 投稿命中率:25.0
经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。

594 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2017-09-02 1dd96cb3m86(暂无匿称)

第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审

697 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2020-03-24 cpufanfan

感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表:
那应该是送外审了，祝好运

186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运

522 4

展开4条回复

[GetPortalCommentsPageByObjectIdResponse(id=2242902, encodeId=f1f1224290200, content=with editor接近1个月 Decision in Process接近一周效率真的很低, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=31, replyNumber=5, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Dec 16 13:55:15 CST 2024, time=2024-12-16, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2239116, encodeId=ca962239116dd, content=with editor 12天了，好焦虑, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=399, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=9a645211081, createdName=1475d94am10暂无昵称, createdTime=Mon Nov 25 17:34:54 CST 2024, time=2024-11-25, status=1, ipAttribution=安徽省), GetPortalCommentsPageByObjectIdResponse(id=2138167, encodeId=7d8a213816eae, content=请问投稿后一般with editor几天会送审？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=295, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220223/2c35a2a30a744be1ae1bf73f9aed6914/c61b34f65a0049d0a7fe43196800d807.jpg, createdBy=a6891663153, createdName=1ddf3775m09(暂无匿称), createdTime=Sun May 21 12:25:43 CST 2023, time=2023-05-21, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2149050, encodeId=618b214905096, content=审稿速度:2.0 | 投稿命中率:25.0 偏重的研究方向：肝癌 经验分享：with editor 1周，10号送外审，期待中, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=207, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83ephyuqAymtlDMRohLN2uuz46RrlziauJLvAbftD6K7tvs9bP6BDQuWkA1v323SR995RqtibaobUd3tA/132, createdBy=8a742285606, createdName=121d577cm33(暂无昵称), createdTime=Thu Jul 20 19:22:03 CST 2023, time=2023-07-20, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2108161, encodeId=2f0821081610e, content=想问问这个杂志收中药单体的机制研究文章吗？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=262, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=ea225571309, createdName=ms5000001189510088, createdTime=Fri Dec 30 17:16:04 CST 2022, time=2022-12-30, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=1240992, encodeId=adf712409924e, content=With Editor 一个周了，不知道会怎么样, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=270, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=67bf2292629, createdName=121ec805m86(暂无昵称), createdTime=Thu Aug 25 18:03:10 CST 2022, time=2022-08-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=515810, encodeId=628d51581005, content=审稿速度:1.0 | 投稿命中率:25.0 经验分享：投稿后20天拒搞，给机会再投（状态为revised），两个reviewer提了一堆问题，因为问题比较多当时挺担心的。前后花了4个月时间补实验，并照审稿人意见逐条修改，认真回答。修回后1个月状态变为accept-with minor revise，按照review意见进行修改后10接收。从投到接收共6个多月，杂志速度挺快，主要是自己等小鼠补实验花费了两三个月时间。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=594, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=77d21654857, createdName=lss7259, createdTime=Fri Oct 09 13:09:00 CST 2015, time=2015-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=546222, encodeId=aec854622249, content=第一次投稿的时候三天就拒绝了.这次投稿.在副主编里with editor8天了.好担心.希望能送外审, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=697, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2017/10/24/60770a300e3f99e9c54e85067da5d704.jpg, createdBy=45db1636816, createdName=1dd96cb3m86(暂无匿称), createdTime=Sat Sep 02 16:33:00 CST 2017, time=2017-09-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=587302, encodeId=c66158e302d9, content=感觉好慢呀。under review状态都变了三次了。不知道什么情况。186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, beContent=186****1268 2020-03-22 00:00:00 发表: 那应该是送外审了，祝好运, objectType=tool_impact_factor, channel=null, level=null, likeNumber=522, replyNumber=4, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200709/0f27fd1aef80482ea0f83a6fa7781324/3dd7506f6bfd4983a69ad1f8da6d58f7.jpg, createdBy=e9415194902, createdName=cpufanfan, createdTime=Tue Mar 24 00:00:00 CST 2020, time=2020-03-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1061122, encodeId=4a7f10611226d, content=审稿速度:2.0 偏重的研究方向：临床转化;基础研究 经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=501, replyNumber=2, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=36db2019043, createdName=心内一科, createdTime=Sat Oct 16 22:36:00 CST 2021, time=2021-10-16, status=1, ipAttribution=)]

2021-10-16 心内一科

审稿速度:2.0
偏重的研究方向：临床转化;基础研究
经验分享：肝病领域的权威杂志，可惜被某李姓长江玩坏了。整天在上面卖NASH和肝I/R的文章，还都是一个套路。都是些NF-kb通路、ASK1/P38通路和GSK3通路，流水线生产的假文章。

501 2

展开2条回复

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务